Correlation Between CD44 and CDK4 Expression with T Stage of Papillary Thyroid Carcinoma
DOI:
https://doi.org/10.52783/jns.v14.2332Keywords:
CD44, CDK4, papillary thyroid cancer, T stage, thyroid cancerAbstract
Background: The most common endocrine malignancy in the world is papillary thyroid carcinoma, with rising numbers worldwide. The prognosis of this tumor is determined by age, size, local invasion and metastasis. Cell proliferation determined tumor size, where cancer stem cell such as CD44 becomes the main driver. Numbers of pathways will affect cell proliferation, CD44 could impact protein such as cyclin dependent kinase 4 (CDK4) which will affect cell cycle, causing increased proliferation which in turn, altering disease progression.
Objective: To analyze correlation between CD44 and CDK4 expression in various T stages of papillary thyroid carcinoma
Methods: This research is observational analytical cross-sectional research. Samples of paraffin blocks from patients diagnosed with papillary thyroid carcinoma from January 2019 to December 20202, who underwent lobectomy, isthmolobectomy and thyroidectomy. Samples then were categorized into groups according to their pathological T (pT) stage. Immunohistochemistry staining was done using CD44 and CDK4 antibodies. Differences of expression across different pT stage groups was done using statistics.
Results and Discussion: No differences in CD44 expression in various pT stage of papillary thyroid carcinoma (p=0.335), no correlation found (p=0.703). No differences in CDK4 expression in various pT stage of papillary thyroid carcinoma (p=0.904), no correlation found (p=0.752). Positive correlation was found between CD44 and CDK4 expression (p=0.0000849, r=0.518).
Conclusion: Various CD44 and CDK4 expression was found in various pT stage of papillary thyroid carcinoma, with positive correlation between CD44 and CDK4.
Downloads
Metrics
References
Rossi, E. D., & Pantanowitz, L. (2023). Typical “BRAFV600E-Like” atypia in papillary thyroid carcinoma: A morphologic sign of a driver mutation. Endocrine Pathology, 34(2), 265–266. https://doi.org/10.1007/s12022-023-09765-1
Ghossein, Ronald A, Asa, Sylvia L, Baloch, Zubair Wahid, et al. Papillary Thyroid Carcinoma, in: WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 10). Available from: https://tumourclassification.iarc.who.int/chapters/53.
Tuttle, R. M., Haugen, B., & Perrier, N. D. (2017). Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and why? Thyroid, 27(6), 751–756. https://doi.org/10.1089/thy.2017.0102
Bai, Y., Kakudo, K., & Jung, C. K. (2020). Updates in the pathologic classification of thyroid neoplasms: A review of the world health organization classification. Endocrinology and Metabolism, 35(4), 696–715. https://doi.org/10.3803/ENM.2020.807
Konturek, A., Barczyński, M., Nowak, W., & Richter, P. (2012). Prognostic factors in differentiated thyroid cancer - A 20-year surgical outcome study. Langenbeck’s Archives of Surgery, 397(5), 809–815. https://doi.org/10.1007/s00423-011-0899-z
Guo, Q., Yang, C., & Gao, F. (2022). The state of CD44 activation in cancer progression and therapeutic targeting. FEBS Journal, 289(24), 7970–7986. https://doi.org/10.1111/febs.16179
Mesrati, M. H., Syafruddin, S. E., Mohtar, M. A., & Syahir, A. (2021). CD44: A multifunctional mediator of cancer progression. Biomolecules, 11(12). https://doi.org/10.3390/biom11121850
Xu, H., Niu, M., Yuan, X., Wu, K., & Liu, A. (2020). CD44 as a tumor biomarker and therapeutic target. Experimental Hematology and Oncology, 9(1), 1–14. https://doi.org/10.1186/s40164-020-00192-0
Fassl, A., Geng, Y., & Sicinski, P. (2022). CDK4 and CDK6 kinases: From basic science to cancer therapy. Science, 375(6577). https://doi.org/10.1126/science.abc1495
Magaki, S., Hojat, S. A., Wei, B., So, A., & Yong, W. H. (2019). An introduction to the performance of immunohistochemistry. Methods in Molecular Biology, 1897, 289–298. https://doi.org/10.1007/978-1-4939-8935-5_25
Ruengwanichayakun, P. (2021). Histochemical scoring assessment (H-score). Asian Archives of Pathology, 3(1), 13.
Rashid, F. A., Munkhdelger, J., Fukuoka, J., & Bychkov, A. (2020). Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma—a contemporary systematic review. Gland Surgery, 9(5), 1878–1900. https://doi.org/10.21037/gs-20-430
Lim, H., Devesa, S. S., Sosa, J. A., Check, D., Cari, M., Branch, E., & Cancer, N. (2021). Trends in thyroid cancer incidence and mortality in the United States 1974-2013. Journal of the American Medical Association, 317(13), 1338–1348. https://doi.org/10.1001/jama.2017.2719.Trends
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., Schuff, K. G., Sherman, S. I., Sosa, J. A., Steward, D. L., Tuttle, R. M., & Wartofsky, L. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1–133. https://doi.org/10.1089/thy.2015.0020
Golbert, L., De Cristo, A. P., Faccin, C. S., Farenzena, M., Folgierini, H., Graudenz, M. S., & Maia, A. L. (2017). Serum TSH levels as a predictor of malignancy in thyroid nodules: A prospective study. PLoS ONE, 12(11), 1–12. https://doi.org/10.1371/journal.pone.0188123
Haymart, M. R. (2009). Understanding the Relationship Between Age and Thyroid Cancer. The Oncologist, 14(3), 216–221. https://doi.org/10.1634/theoncologist.2008-0194
Derwahl, M., & Nicula, D. (2014). Estrogen and its role in thyroid cancer. Endocrine-Related Cancer, 21(5), T273–T283. https://doi.org/10.1530/ERC-14-0053
Ding, J., Wu, W., Fang, J., Zhao, J., & Jiang, L. (2020). Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma. Scientific Reports, 10(1), 1–8. https://doi.org/10.1038/s41598-020-60199-9
[19] Tang, K. T., & Lee, C. H. (2010). BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications. Journal of the Chinese Medical Association, 73(3), 113–128. https://doi.org/10.1016/S1726-4901(10)70025-3
Han, S. A., Jang, J. H., Won, K. Y., Lim, S. J., & Song, J. Y. (2017). Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma. Pathology Research and Practice, 213(8), 956–963. https://doi.org/10.1016/j.prp.2017.05.002
Ryu, Y. J., Choe, J. Y., Lee, K., & Ahn, S. H. (2020). Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma. Oncology Letters, 19(1), 343–349. https://doi.org/10.3892/ol.2019.11087
Rohani, P., Noroozinia, F., Modarresi, P., & Abbasi, A. (2017). CD44 standard isoform; Not a good marker for colon cancer. International Journal of Cancer Management, 10(9). https://doi.org/10.5812/ijcm.9166
Kawai, T., Iwata, K., Shinotsuka, Y., Kubo, S., Masuoka, H., Yabuta, T., Hirokawa, M., Nakamura, H., Miyauchi, A., & Komai, K. (2019). CD44v8-10 and CD44s are age-dependently expressed in primary cultured papillary thyroid carcinoma cells and are associated with cell proliferation. Kobe Journal of Medical Sciences, 65(1), E1–E9.
Miyazaki, H., Takahashi, R., Prieto-vila, M., & Kawamura, Y. (2018). CD44 exerts a functional role during EMT induction in cisplatin- resistant head and neck cancer cells.
Sobhani, N., Angelo, A. D., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019). Combinations in Breast Cancer. Cells, 8(4), 1–24
Pita, J. M., Raspé, E., Coulonval, K., Decaussin-Petrucci, M., Tarabichi, M., Dom, G., Libert, F., Craciun, L., Andry, G., Wicquart, L., Leteurtre, E., Trésallet, C., Marlow, L. A., Copland, J. A., Durante, C., Maenhaut, C., Cavaco, B. M., Dumont, J. E., Costante, G., & Roger, P. P. (2023). CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. Frontiers in Endocrinology, 14(October), 1–24. https://doi.org/10.3389/fendo.2023.1247542
Dai, M., Zhang, C., Ali, A., Hong, X., Tian, J., Lo, C., Fils-, N., Burgos, S. A., Ali, S., & Lebrun, J. (2016). CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. Nature Publishing Group, October, 1–15. https://doi.org/10.1038/srep35383
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
